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                                                      ABSTRACT 
TITLE: HISTOPATHOLOGICAL ANALYSIS OF UTERINE CORPUS 
MALIGNANCIES AND THE ROLE OF IMMUNOHISTOCHEMISTRY TO 
DISTINGUISH BETWEEN ENDOMETRIAL ADENOCARCINOMA AND 
ENDOCERVICAL ADENOCARCINOMA. 
The study was carried out   in Thanjavur Medical college  and Hospital in Tamil Nadu 
over a period of three and half years. In a total of 7910 gynaecological specimens received, 
761 cases (9.6%) were reported to be uterine corpus neoplasms including benign and 
malignant neoplasms. There are 60 malignant  uterine corpus neoplasms reported out of 761 
cases (7.8%). The following histopathological diagnosis were reported  within this  given 
period of time are 49 cases of endometrial carcinoma, 4 cases of leiomyosarcoma, 4 cases of 
choriocarcinoma, 1 case of endometrial stromal sarcoma, 1 case of germ cell tumors and 1 
case of carcinosarcoma. The inference is that endometrial carcinoma is the most common 
malignancy observed in our study as seen in other literatures. In endometrial 
adenocarcinoma, Endometriod adenocarcinoma NOS type is the most common pattern noted. 
76% of cases are exhibiting grade I features which is not in concordance with other studies, 
where Grade II features is prevalent. Around 80 % of tumors are Stage I tumors and hence 
simple hysterectomy is sufficient. Although stage II,  III and higher grade tumors require 
Radical  Hysterectomy with lymphadenectomy. 
The other histologic variants documented in our study are 1 case of uterine papillary 
serous carcinoma, 1 case of clear cell adenocarcinoma, 1 case of squamous cell carcinoma in 
an elderly women presenting with pyometra, and 2 cases of poorly differentiated carcinoma.  
The Immunohistochemical stains used in our study are ER and P16 . The expression 
of both the markers were studied in a total of 20 small biopsy / curettings which includes 10 
cases of endometrial adenocarcinoma and 10 cases of endocervical adenocarcinoma. 90% of 
endocervical adenocarcinoma expressed P16 and 40% of endometrial adenocarcinoma 
expressed P16. 
ER expression was 60% in endometrial adenocarcinoma and 30 % in endocervical 
adenocarcinoma.Both markers were positive in 30% of cases and no single marker is 
diagnostic to distinguish endometrial adenocarcinoma from endocervical adenocarcinoma. 
Various literatures rtecomment panel of IHC markers to distinguish this two. The panel 
should include ER, PR, Vimentin, CEA, P16.  
ER, PR, and vimentin is predominantly positive in Endometrial adenocarcinomas 
whereas CEAand P16 is positive in Endocervical adenocarcinomas. 
Recent studies have shown that Conventional three panel markers  ER/Vimentin/CEA 
panel is sufficient, appropriate and useful. Ancillary PR and P16 INK 4a  add  no value to the 
performance of the conventional three marker ER/Vimentin/CEA panel. 
 
Key words: Uterine corpus malignancies,  Endometrial carcinoma, Immunohistochemistry 
ER, P16,  
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                                            INTRODUCTION: 
                             The uterine corpus malignancies represent the third  most common  
site of malignancy of the female genital system, following cervix and ovary. This  
neoplasm includes epithelial, mesenchymal, mixed epithelial and mesenchymal 
tumours and trophoblastic tumours3. 
                              Endometrial carcinoma is the most common malignancy in 
developed countries and is frequently associated with obesity. Two major types were 
distinguished. Type I and Type II. Type I is estrogen dependent tumours, which 
follows hyperplasia-carcinoma sequence. These accounts for about 90% cases4. Type 
II is non – estrogen dependent tumours which occurs in old age and is more 
aggressive. 
                               In developing countries Gestational trophoblastic disease is more 
common. Risk factors include a history of  prior gestational trophoblastic disease, 
blood group A women married to group O men and a diet low in vitamin A3. 
Carcinosarcoma is a mixed epithelial and mesenchymal tumour, its prognosis is worse 
than that of other members of the epithelial category. 
                                  Lower uterine segment carcinoma mainly adenocarcinoma 
endometrium versus endocervix is difficult to distinguish since there is substantial 
morphologic overlap between them. The treatment modality varies for both entities. 
Endometrial adenocarcinoma is treated with simple hysterectomy and bilateral 
salphingo-oopherectomy while endocervical adenocarcinoma is treated with radical 
hysterectomy, pelvic lymphadenectomy and primary chemo-radiotherapy. Hence the 
difference in the therapeutic approaches necessitate attempts to distinguish these two 
tumors is paramount. 
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Application of immunohistochemical markers made its way. Several studies have 
attempted using a panel of IHC markers and found relatively good result in 
distinguishing between these adenocarcinomas. The most common panel includes 
antibody against Estrogen receptor (ER), progesterone receptor (PR), vimentin , 
carcinoembryonic antigen (CEA), and P168,9,11,12. 
They were used in different combinations in different studies to minimize the 
differences. 
CEA and P16 positivity were  more common in cervical adenocarcinomas about 62 % 
and 94% each respectively, Vimentin, ER, PR, were more common in endometrial 
adenocarcinomas, showing  70%, 90%, 96% positivity each37 
                                Our study is directed towards the histopathological analysis of 
uterine corpus malignancies and its histologic subtypes correlated with age, the 
presentation,  grade and staging of the tumor. The other part of the study is to  analyse 
the role of Immunohistochemical markers ER and P16 to distinguish between 
endometrial adenocarcinoma vs. endocervical adenocarcinoma in biopsy/ curettage 
specimens.  
The results have been compared with other journals and literature. 
 
 
 
 
AIM OF THE STUDY: 
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1. To study the proportion of uterine corpus malignancies reported in the department 
of pathology, Thanjavur medical college from the period of January 2012 till 2015 
June. 
2. To analyse the various histopathological types of uterine corpus malignancies. 
3. To classify and grade the endometrial carcinoma in order to predict the prognosis. 
4. Lower uterine segment adenocarcinoma is a diagnostic difficulty, hence with help 
of two IHC markers endometrial adenocarcinomas can be distinguished from 
endocervical adenocarcinomas using ER and p16 IHC markers. 
 
 
 
 
 
 
 
 
 
 
 
 
MATERIALS & METHODS: 
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STUDY PERIOD: January 2012  till June 2015 
                         This study was conducted for, a period of  three and half years in 
Thanjavur medical college and hospital. It is both a retrospective and a prospective 
study.   
                          Totally we have received 7910 gynaecological specimens for 
histopathological examination. out of which 761 cases were reported as uterine corpus 
neoplasms including both benign and malignant tumors which excludes cervical, 
ovarian and adnexal neoplasms. out of which all cases of uterine corpus malignancy 
were recorded which counts about 60 in number and are taken for  histopathological 
analysis . 
                          The second objective is to analyse the role of immunohistochemical 
markers ER and P16 to distinguish the low grade endometrial adenocarcinoma versus 
endocervical adenocarcinoma. For Immunohistochemistry analysis, 10 cases of low 
grade endometrial adenocarcinoma and 10 cases of endocervical adenocarcinoma 
small biopsy specimen were taken for IHC study with ER and P16 markers. 
 
 
 
 
  
 INCLUSION CRITERIA: 
               1. All uterine corpus carcinomas 
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               2. All uterine corpus sarcoma 
               3. Mixed malignant tumors 
               4. Malignant gestational trophoblastic disease 
               5. other malignant tumors 
 EXCLUSION CRITERIA: 
             1. Benign uterine corpus neoplasms 
             2.Endometrial hyperplasia with atypia 
             3. Endometrial intraepithelial neoplasia  
             4. cervical neoplasms 
             5. ovarian neoplasms 
             6. metastatic neoplasms. 
HISTOPATHOLOGICAL EXAMINATION:  
Endometrial curetting/biopsy specimen were fixed in 10% neutral buffered formalin 
in Toto, and also tissue bits were taken from selective areas of  the hysterectomy 
specimens fixed in 10% neutral buffer formalin followed by routine processing.   
Sections of 3-4 micron thickness was  made, stained with haematoxylin and eosin  
and subjected to histopathological examination. 
 
 
IMMUNOHISTOCHEMICAL EVALUATION: 
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For IHC study, 10 cases of endometrial adenocarcinoma and 10 cases of endocervical 
adenocarcinoma diagnosed in small biopsies were taken and subjected to ER and P16 
antibody markers study. The slides were then analysed and correlated with HPE 
report. 
Immuohistochemical analysis were done in paraffin embedded tissue 
samples using the Next Generation Micro-Polymer HRP system based on non-biotin 
polymeric technology provided by Thermo Scientific Ultra vision Quanto detection 
system for Immunohistochemistry. 4 µ thick sections from formalin fixed paraffin 
embedded tissue samples were transferred on to gelatin coated slides. Heat induced 
antigen retrieval was done.  
   The antigen was bound with monoclonal antibody and then detected by the 
addition of secondary antibody conjugated with horse radish peroxidase-polymer and 
diaminobenzidine substrate.  
Immunohistochemistry procedure: 
Slide Preparation: 
1. Sections with a thickness of 4 µ were cut from formalin fixed paraffin 
embedded tissue samples and transferred to gelatin-chrome alum coated 
slides. 
2. The slides were incubated for overnight at 58ºC. 
3. The sections  were  deparaffinised   in  xylene  for 15 minutes x  
2changes. 
4. The sections were dehydrated with absolute alcohol for 5 minutes for 2 
changes. 
5. The sections were then washed in tap water for 10 minutes. 
6. The slides were then immersed in distilled water for 5 minutes. 
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Antigen Retrieval: 
1. Heat induced antigen retrieval was done with microwave oven in 
appropriate temperature with appropriate buffer for 20 minutes. This step 
unmasks the antigenic determinants of fixed tissue sections. 
2. The slides were then cooled to room temperature for 20 minutes and 
washed in running tap water for 5 minutes. 
3. The slides were then rinsed in distilled water for 5 minutes. 
4. They were washed with appropriate wash buffer (citrate buffer) for 5 
minutes x 2 changes. 
5. Peroxidase block was applied over the sections for 10 minutes. 
6. The slides were washed in citrate buffer for 5 minutes x 2 changes. 
7. Sections were covered with peroxidase block for 5 minutes. 
Antibody application: 
1. The sections  were  drained  (without washing) and appropriate 
 primary antibody was applied over the sections and incubated for 30 
minutes. 
2. The slides were washed in citrate  buffer for 5 minutes x 2 changes. 
3. The slides were covered with Primary antibody amplifier for 10 minutes. 
4. The slides were washed in citrate buffer for 5 minutes x 2 changes. 
5. The slides were covered with HRP micropolymer Quanto for 10 minutes. 
6. The slides were washed in citrate buffer for 5 minutes x 2 changes. 
Chromogen application: 
1. DAB substrate was prepared by diluting 1 drop of DAB Quanto 
chromogen to 1 ml of DAB Quanto buffer. 
2. DAB substrate solution was applied on the sections for 5 minutes. 
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3. The slides were washed in distilled water for 2 minutes. 
4. The sections were counterstained with Hematoxylin  for 2 seconds. 
5. The slides were washed in running tap water for 5 minutes. 
6. The slides were air dried, mounted with DPX. 
Alternate methods of antigen retrieval 
• Pressure cooker antigen retrieval 
• Microwave and trypsin antigen retrieval 
IMMUNOHISTOCHEMISTRY SCORING SYSTEM 
Estrogen receptor scoring was done using Allred scoring system 
Allred scoring system:39 
The score was given based on the percentage of proportion of cells taken the stain and 
the intensity of  the stain 
 
Allred score =proportion of cells  taken  nuclear stain +  in score and intensity score 
 
Proportion of tumor 
cells taken nuclear stain  
  
Score 
No cells taken 0 
<1% 1 
1-10% 2 
11-33% 3 
34-66% 4 
67-100% 5 
 
Intensity of the stain – 
ER 
 
SCORE 
No staining 0 
Weak 1 
Intermediate 2 
Strong 3 
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maximum score =8 
minimum score = 0 
 Results    ≤ 2 = negative 
                 3-8 = positive 
P16- SCORING: 17 
Tumor was given a score  according to the intensity of nuclear staining. 
 and extent of stained cells. 
Intensity of nuclear 
staining  
Score 
No staining 0 
Weak staining 1 
Moderate staining 2 
Strong staining 3 
  
P16 SCORE=  Intensity  of the stain X Extent of positivity     
 maximum score = 12         
 minimum score = 0  
RESULT: ≤ 4 : negative 
                 ≥ 4 : positive 
 
                       REVIEW OF LITERATURE 
Extent of stained cells Score 
No staining 0 
1-10% of cells  1 
11-50% 2 
51-80% 3 
81-100% 4 
19 
 
UTERINE CORPUS MALIGNANCIES 
WHO HISTOLOGICAL CLASSIFICATION OF TUMORS OF UTERINE 
CORPUS3 
ENDOMETRIAL TUMORS AND RELATED LESIONS 
Endometrial carcinoma 
 Endometriod adenocarcinoma 
 Mucinous adenocarcinoma 
 Serous adenocarcinoma 
 Clear cell adenocarcinoma 
 Mixed cell adenocarcinoma 
 Squamous cell carcinoma 
 Transitional cell carcinoma 
 Small cell carcinoma 
 Undifferentiated carcinoma 
 Others 
Endometrial hyperplasia 
Nonatypical hyperplasia 
 Simple 
 Complex 
 
Atypical hyperplasia 
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 Simple 
 Complex 
Endometrial polyp 
Tamoxifen related lesions 
MESENCHYMAL TUMORS: 
Endometrial stromal and related tumors 
 Endometrial stromal sarcoma 
 Endometrial stromal nodule 
 Undifferentiated endometrial sarcoma 
Smooth muscle tumors: 
Leiomyosarcoma 
 Epitheloid variant 
 Myxoid variant 
Smooth muscle tumor of uncertain malignant potential 
Leiomyoma not otherwise specified 
        Histologic variants 
 Mitotically active variant 
 Cellular variant 
 Hemorrhagic cellular variant 
 Epitheloid variant 
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 Myxoid variant 
 Atypical variant 
 Lipoleiomyoma variant 
Growth pattern variants: 
 Diffuse leiomyomatosis 
 Dissecting leiomyoma 
 Intravenous leiomyomatosis 
 Metastasizing leiomyoma 
Miscellaneous mesenchymal tumors: 
 Mixed endometrial stromal and smooth muscle tumor 
 Perivascular epitheloid cell tumor 
 Adenomatoid tumor 
Other malignant mesenchymal tumor 
Other benign mesenchymal tumors 
MIXED EPITHELIAL AND MESENCHYMAL TUMORS 
 Carcinosarcoma (MMMT) 
 Adenosarcoma 
 Carcinofibroma 
 Adenofibroma 
 Adenomyoma 
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GESTATIONAL TROPHOBLASTIC DISEASE: 
Trophoblastic neoplasms 
 Choriocarcinoma 
 Placental site trophoblastic tumor 
 Epitheloid trophoblastic tumor 
Molar pregnancies    
 Hydatiform mole 
 Complete  
 Partial 
 Invasive  
 Metastatic 
Non-neoplastic, non molar trophoblastic lesions 
 Placental nodule and plaque 
 Exaggerated placental site. 
Miscellaneous tumors: 
 Sex cord like tumors 
Neuroectodermal tumors 
Melanotic paraganglioma 
Tumors of germ cell type 
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lymphoid and Hematopoetic tumors 
    Malignant lymphoma 
     Leukemia 
SECONDARY TUMORS 
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                                  ENDOMETRIAL ADENOCARCINOMA 
It is the primary malignant epithelial tumour arising in the endometrium . 
Types :Type I and Type II 
Type I endometrial  adenocarcinoma 
Constitutes about 80- 85 % of cases. It is estrogen dependent  tumor follows the 
endometrial hyperplasia – carcinoma sequence. It includes the well and moderately 
differentiated tumor, predominantly of  endometriod type. 
:  Risk factors : prolonged oestrogen exposure as in nulliparity, late menopause, 
anovulatory cycles with polycystic ovarian syndrome where there is unopposed 
hyperestrogen secretion happening  stimulating the follicles, exogenous hormone 
replacement  therapy,  obesity which is an independent risk factor for carcinoma. It is 
by the action of peripheral conversion of  fats into  estrogen by aromatase enzyme. 
ESSENTIAL DIAGNOSTIC CRITERIA OF ENDOMETRIAL 
INTRAEPITHELIAL NEOPLASIA (EIN)73 
EIN CRITERIA COMMENTS 
1. Architecture  Gland area exceeds that of stroma, usually in a 
localized region 
2. Cytological alterations Cytologically differs between architecturally 
crowded focus and background 
3. Size >1mm Maximum linear dimension should exceed 1 mm. 
smaller lesions have unknown natural history. 
Exclude benign mimics and cancer 
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Type II endometrial adenocarcinoma: 
This is non estrogen dependent carcinoma which occurs in old post-menopausal 
women. 
These are high grade tumors with high grade nuclear features such as serous 
adenocarcinoma and clear cell adenocarcinoma. They have an aggressive behavior. 
CHARECTERISTICS OF TYPE I & TYPE II ENDOMETRIAL 
CARCINOMA6 
CHARACTERISTICS TYPE I  TYPE II 
Age  55-65 yrs 65-75 yrs 
Clinical setting Unopposed estrogen 
Obesity 
Hypertension 
Diabetes 
Atrophy 
Thin physique 
Morphology Endometriod Serous 
Clear cell 
Mixed mullerian tumor 
 
Precursor Hyperplasia  Serous endometrial 
intraepithelial carcinoma 
Mutated genes/genetic 
abnormalities 
PTEN 
ARID1A 
PIK3CA 
KRAS 
MSICTNNB1 
TP53 
Aneuploidy 
PIK3CA 
CHD4 
PPP2R1A 
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TP53 
Behaviour  Indolent 
Spreads via lymphatics 
Aggressive 
 intraperitoneal and 
lymphatic spread 
 
Clinical features: 
Post menopausal bleeding 
Abnormal uterine bleeding earlier in life. 
In endometiod adenocarcinoma may be manifested by obesity, infertility and late 
menopause.  
Endometriod adenocarcinoma: 
This is the most common type, The tumor resembles that of normal endometrium.  It 
is characterized by glandular or villoglandular pattern  lined by simple to 
pseudostratified  columnar cells that have their long axis perpendicular to the 
basement membrane with rounding or elongated nuclei polarized in the same 
direction.  
Spectrum of histologic differentiation from very well differentiated carcinoma to 
undifferentiated carcinoma as the glandular differentiation decreases and is replaced 
by solid nests and sheets of cells. 
with four different variants documented namely:  
 Endometriod adenocarcinoma with squamoid differentiation  
 Villoglandular variant 
 Secretory variant 
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 Ciliated cell variant. 
Variant with squamoid differentiations criteria for diagnosis: 
1. Keratinization demonstrated with standard staining techniques 
2. Intercellular bridge and/or 
3. Three or more of the following four  criteria 
a. Sheet like growth without gland formation or palisading 
b. Sharp margins 
c. Eosinophilic and thick glassy cytoplasm 
d. A decreased nuclear to cytoplasmic ratio as compared with foci elsewhere 
in the same tumor 
Villoglandular variant 
Next most common variant.  Here the tumor cells are arranged in numerous villous 
fronds with a delicate central core. The cells are arranged in perpendicular to the 
basement membrane in contrast to the more complex papillary architecture and high 
grade nuclear features.This is usually seen involving part of a low grade endometriod 
carcinoma . 
Secretary variant: 
The glands are lined by epithelium with voluminous glycogen vacuoles in the sub 
nuclear location reminiscent of early secretary endometrium but can be identified by 
the confluent ,cribriform or villoglandular  pattern . 
Ciliated cell variant: 
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 It is a very rare variant. The glands are lined by ciliated cells which resembles tubal 
epithelium with malignant features. ciliated cells may be seen in endometriod 
adenocarcinoma but to define as this variant it should be present in majority of glands. 
 
MUCINOUS ADENOCARCINOMA 
These are grade I tumors with favourable prognosis. The tumor cells contain 
intracytoplasmic mucin unlike endometriod  and clear cell adenocarcinoma which has  
intraluminal mucin. 
Incidence -  9% of endometrial carcinoma 3 
Variants of mucinous adenocarcinoma: 
Microglandular adenocarcinoma 
Intestinal type with goblet cells. 
TNM AND FIGO STAGING OF NON- TROPHOBLASTIC TUMOURSNOF 
THE UTERINE CORPUS 
TX  Primary tumor cannot be assed 
T0  No evidence of primary tumor 
Tis 0 Carcinoma in situ 
T1 1 
   A 
   B 
   C 
CONFINED TO CORPUS UTERI 
Limited to endometrium 
<1/2 of myometrial invasion 
>1/2 of myometrial invasion  
T2 II TUMOR INVADES CERVIX 
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  A 
  B 
Endocervical gland involvement  
Cervical stroma invasion 
T3 III 
   A 
 
 
   B 
   C/ N1 
LOCAL AND REGIONAL SPREAD 
Direct extension or metastasis to serosa 
and/or adnexa 
Ascitic fluid or peritoneal washing + for 
tumor cells 
Vaginal involvement 
Metastasis to pelvic or paraaortic node 
 
T4 IV 
   A 
   B/M1 
 
Bladder mucosa and/or bowel mucosa 
Distant metastasis 
 
N REGIONAL LYMPHNODES 
     X Cannot be assessed 
     0 No node metastasis 
     1 Regional node metastasis 
M DISTANT METASTASIS 
     0 No distant metastasis 
   1 Distant metastasis 
 
Grading of type 1( endometriod and mucinous) endometrial adenocarcinoma by FIGO 
grading system38 
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It is based on the degree of differentiation as defined by percentage of glandular and 
solid components ( areas of squamous differentiation are not considered regions of 
solid growth)59 
Grade1: <5%   solid areas (non squamous,non-morular) growth pattern 
Grade2: 6-50%  
Grade3: >50% 
Nuclear pleomorphism inappropriate for the tumor architecture increase the tumor 
grade by 1 degree. 
SEROUS ADENOCARCINOMA: 
It is an aggressive high grade tumor with high recurrence rate, classified as type II 
endometrial carcinoma. It is not associated with exogenous or endogenous estrogen 
stimulation. Usually arises from atrophic endometrium. It has a tendency for deep 
myometrial invasion and extensive lymphatic invasion.The precursor lesion is serous 
endometrial intraepithelial carcinoma also called as endometrial carcinoma in situ and 
surface serous carcinoma. But it carries the same prognosis since dissemination 
outside the uterus in the absence of invasion has also been noted. 
Histopathology: 
The neoplastic cells are arranged in complex papillary pattern having broad 
fibrovascular core with highly pleomorphic cytological changes. 
The cells and nuclei are rounded and lack a perpendicular orientation to the basement 
membrane. The nuclei are poorly differentiated apically situated and have a large 
brightly eosinophilic macronucleoli. 
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There are often atypical mitosis , bizarre multinucleated cells are commonly present. 
Psamoma bodies are found in 30 % cases. Prominent sloughing of cells are present. 
CLEAR CELL ADENOCARCINOMA: 
These are the other type II adenocarcinoma, less common than serous type. Incidence- 
1-5% occurs in old age group of people3 .Adenocarcinoma exhibiting clear cells and 
hobnail appearance. There are three types of pattern arrangement noted such as, Solid, 
tubulocystic or papillary patterns or a combination of these three. They have a 
relatively better prognosis than serous adenocarcinoma. 
Histopathology: 
These cells typically have clear , glycogen filled cytoplasm  and hob nail cells that 
project in to the lumens. Nuclei are highly pleomorphic, bizarre and multi nucleated. 
Occasionally the cytoplasm is eosinophilic and  granular like concocts.  
MIXED ADENOCARCINOMA: 
Tumors exhibiting both type I and type II endometrial carcinoma, the minor type 
should comprise atleast 10 % of total volume of tumor. More than 25 % of type II 
tumors carries a poor prognosis. 
SQUAMOUS CELL CARCINOMA: 
This is an uncommon tumor. So far only 70 cases have been documented in 
literature3.The tumor cells composed of squamous cells with varying degree of 
differentiation. Its includes a rare verrucous variant.  
Usually occurs in postmenopausal women and is often associated with cervical 
stenosis and pyometra. 
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It should be differentiated from SCC arising from Ca cervix extending to 
endometrium and endometriod adenocarcinoma with squamous differentiation. 
It carries a poor prognosis although verrucous variant may be more favourable. 
TRANSITIONAL CELL CARCINOMA: 
The tumor cells resembles urothelial transitional cells, which should constitute about 
90% of tumor cell volume. 
They are grade 2- grade 3 tumors presenting as polypoid or papillary mass 
It should be differentiated from urothelial carcinoma from bladder and ovary. 
HPV type 16 is associated with this tumor. 
SMALL CELL CARCINOMA: 
This tumor comprises less than 1 % incidence. Uncommon tumor in endometrium. 
The histology is similar to that of small cell carcinoma in other organs. The prognosis 
is far better in stage I disease with a 5 year survival of about 60 % unlike in other 
sites. 
UNDIFFERENTIATED CARCINOMA: 
These tumors lack any kind of differentiation.  
GENETICS OF ENDOMETRIAL CARCINOMA 3,6 
Inactivation of PTEN tumor suppressor pathway- endometrial type 1 adenocarcinoma 
                     PTEN checks cell division and enables apoptosis via AKT- growth 
regulatory pathway. When PTEN function is lost, PI3K/AKT pathway becomes 
overactive and enhances the ability of oestrogen receptors to turn on the expression of 
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its target genes, leading to overgrowth of cell types that depend on estrogen for 
trophic signals such as endometrium and mammary epithelial cells  
Normally PTEN is expressed only during estrogen driven proliferative phase of the 
endometrium. 
 TP53 tumor suppressor pathways mutation – endometrial type II adenocarcinoma. 
         Mutant protein accumulates in nuclei which can be demonstrated by IHC in 
most serous (type II adenocarcinoma). 
Its expression is associated with poor clinical outcome 
 
 
MOLECULAR DELINEATION OF PREMALIGNANT DISEASE: 
 The earliest molecular change: loss of PTEN – are detectable at a stage before 
glands have undergone any change in the morphology 
 Followed by accumulation of genetic damage MSI , KRAS mutation 
emergence of histologically evident monoclonal lesions. 
GENETIC SUSCEPTIBILITY: 
Majority of cases are sporadic but rarely present as a manifestation of multicancer 
familial syndromes, examples include: 
                HNPCC- hereditary non polyposis colon cancer- caused by DNA mismatch 
repair genes that produce constitutive microsatellite instability. 
               Cowden syndrome: germ line PTEN inactivation. 
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MESENCHYMAL TUMORS: 
Uterine mesenchymal tumors are derived from mesenchyme of the corpus consisting 
of endometrial stroma, smooth muscle and blood vessels or admixtures of these.  
The most common mesenchymal malignant tumor of the uterine corpus are 
1. Leiomyosarcoma 
2. Endometrial stromal tumors 
Clinical features: 
Uterine enlargement, abnormal uterine bleeding, or pelvic pain. 
 
ENDOMETRIAL STROMAL TUMOR: 
2014 classification. 
 Endometrial stromal sarcoma  
                                low grade 
                                High grade 
 Undifferentiated endometrial sarcoma 
 Endometrial stromal nodule 
The average age of presentation is 45 years, usually presents with vaginal bleeding. 
Microscopically these tumor cells resembles that of proliferative endometrial stromal 
cells. The individual cells are uniform and predominantly oval in shape. Individual 
cells are enveloped by reticulin fibers  They are divided in to benign and malignant 
groups based on the type of margin of the lesion. 
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 Endometrial stromal nodule  have pushing margins which is a benign tumor 
Endometrial stromal sarcoma have infiltrative margins which is a malignant tumor. 
ENDOMETRIAL STROMAL SARCOMA LOW GRADE: 
It’s a rare tumor of the uterus comprising for only 0.2 % of all genital tract 
malignancy 
GROSS: 
Solitary well delineated predominantly intramural mass but invasion of the 
myometrium is more common 
C/S: yellow to tan , soft, cystic and myxoid degeneration as well as necrosis and 
haemorrhage are seen occasionally. 
Localization:         metastasis is rare 
extrauterine extension is present in one third of cases , which is seen as worm like 
plugs of tumor within the vessel of broad ligament and adnexa. 
Histopathology: Low grade endometrial stromal sarcoma  
Densely cellular tumor  
composed of uniform oval to spindled cells of endometrial stromal type.  
significant atypia and pleomorphism are absent. 
Rich network of delicate small arterioles resembling the spiral arterioles of late 
secretory endometrium that supports the proliferating cells. 
High mitotic index does not itself alter the diagnosis. 
Other cellular changes noted are: 
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1. Cells with foamy cytoplasm, foamy histiocytes 
2.
 Endometrial type glands seen in 10-11% of tumors 3 
3. Sex cord like structures 
4. Myxoid and fibrous change 
5. Perivascular hyalinization and stellate pattern of hyalinization 
6. Necrosis is typically absent 
7. Special stain: reticulin stain : dense network of fibrils surrounding individual 
cells or small group of cells 
8. Smooth muscle differentiation (spindle or epitheloid) may develop but limited 
to <30% of the tumor 
9. If smooth muscle component is > 30% - it is called as MIXED 
ENDOMETRIAL STROMAL AND SMOOTH MUSCLE TUMOR 
 
Differential diagnosis:  
1. stromal nodule 
2. Intravenous leiomyomatosis  
3. Adenomyosis with sparse glands  
4. Adenosarcoma 
In biopsy material it is highly impossible to distinguish low grade ESS from a 
stromal nodule or leiomyoma or a non neoplastic stromal proliferation. 
Treatment 
        Resection, radiation therapy, progestin therapy or a combination. 
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Prognosis: 
Indolent and late recurrences 
5 year survival rate from 67% to 100% 
Pulmonary metastasis occur in 10% of stage I tumors. 
UNDIFFERENTIATED ENDOMETRIAL SARCOMA: 
It is otherwise called as undifferentiated uterine sarcoma 
Macroscopy:  
One or more polypoid , grey to yellow fleshy endometrial masses with prominent 
haemorrhage and necrosis. 
Histopathology : 
Marked atypia and abundant mitotic activity. They lack the typical growth pattern and 
vascularisation of low grade endometrial stromal sarcoma. They resemble the 
sarcomatous component of carcinosarcoma. 
These sarcomas are negative for estrogen and progesterone receptors. 
Prognosis:  
Aggressive and death occurs from tumor dissemination within 3 yrs after 
hysterectomy. 
MALIGNANT SMOOTH MUSCLE TUMORS: 
 Leiomyosarcoma 
 Smooth muscle tumor of uncertain malignant potential 
 
38 
 
LEIOMYOSARCOMA 
It’s the most common malignant uterine sarcoma comprising about 1% of all uterine 
malignancies. 
Median age of presentation is 50-55 years 
Clinical features:  
Leiomyosarcoma localized to the uterus and leiomyoma produce similar symptoms. 
Rapid increase in size of the uterus after menopause 
Spread: locally or by haematogenous dissemination most often to the lungs 
 
Macroscopy: 
Characteristically solitary , intramural mass , not associated with leiomyomas.  
Average size 8 cm diameter and fleshy with poorly defined margins 
C/S: grey-yellow or pink sectioned , zones of haemorrhage and necrosis are seen 
Histopathology:  
Cellular tumor composed of fascicles of spindled shaped cells that possess abundant 
 eosinophili cytoplasm. 
The nuclei are fusiform , have rounded ends, hyperchromatic with coarse chromatin 
and prominent nucleoli. 
Tumor cell necrosis is typically prominent but need not be present. 
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DIAGNOSTIC CRITERIA FOR LEIOMYOSARCOMA 
 Standard smooth 
muscle differentiation 
Epitheloid 
differentiation 
Myxoid 
differentiation 
Histology Fascicles of cigar 
shaped spindles cells 
with scanty to 
abundant eosinophilic 
cytoplasm 
Rounded cells with 
central nuclei and 
clear to 
eosinophilic 
cytoplasm 
Spindle-shaped 
cells set within an 
abundant myxoid 
matrix 
Low cellularity 
 
Criteria for 
leiomyosarcoma 
Any coagulative tumor 
cell necrosis (CTCN) 
In the absence of 
CTCN the diagnosis 
requires 
Diffuse, moderate to 
severe cytologic atypia 
and  
Mitotic index of >10 
mf/10hpf 
If mf <10mf – this 
group is labelled as 
“atypical leiomyoma 
with low risk of 
recurrence.”  
CTCN+ 
 
 
If CTCN (–) 
Diffuse, moderate 
to severe cytologic 
atypia 
Mitotic index of 
>5mf/10hpf 
CTCN (+) 
 
 
If CTCN (–) 
Diffuse, moderate 
to severe cytologic 
atypia 
Mitotic index of 
>5mf/10hpf 
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CTCN: Abrupt transition from viable tumor to necrotic tumor, ghost outlines of cells 
usual , haemorrhage and inflammation uncommon. 
MISCELLANEOUS MESENCHYMAL TUMORS: 
These are the mesenchymal tumors that do not show smooth muscle or stromal 
differentiation. 
 PERIVASCULAR EPITHELOID CELL TUMOR- uncertain malignant 
potential 
MIXED EPITHELIAL AND MESENCHYMAL TUMORS: 
The tumors composed of both epithelial and mesenchymal component. 
 Carcinosarcoma 
 Adenosarcoma 
 Carcinofibroma 
 
Comments CTCN (-) 
Significant atypia (-) 
Mitotic index(+) 
>15mf/10hpf-  
“ mitotically active 
leiomyoma with 
limited experience” 
 
Focal epitheloid 
differentiation may 
be mimicked by 
cross-sectioned 
fascicles  
Perinodular 
hydropic 
degeneration 
should not be 
included in this 
group. 
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The benign tumors are Adenofibroma, Adenomyoma, Atypical polypoid variant. 
 Benign epithelium Malignant epithelium 
Benign mesenchyme Adenofibroma 
Adenomyoma ( including 
atypical) 
Carcinofibroma 
Malignant mesenchyme Adenosarcoma Carcinosarcoma 
 
CARCINOSARCOMA/ MALIGNANT MULLERIAN MIXED TUMOR/ 
METAPLASTIC CARCINOMA 
This malignant neoplasm composed of admixture of malignant epithelial and 
mesenchymal components. 
This is the most common malignancy of this group. 
Usually occur in elderly postmenopausal women with median age of 65 years, 
occasional cases occur in younger women. 
Possible risk factors:  
Prior pelvic irradiation 
Long term tamoxifen therapy 3 
Clinical features: 
Vaginal bleeding is most frequent. 
Abdominal mass and pelvic pain 
Polypoid mass may prolapse through cervix 
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Most of them can be diagnosed by uterine curettage and is most diagnostic method, 
some need hysterectomy for diagnosis 3 
GROSS: 
Polypoid , bulky, necrotic , hemorrhagic tumor that fill the endometrial cavity and 
deeply invade the myometrium. 
Cartilage or bone tissue are found in many cases and gives a hard consistency. 
Microscopy: 
Malignant epithelial element-  
                                     Glandular- endometriod, serous, or clear cell type  
                                      Non-glandular – squamous or undifferentiated type 
Malignant mesenchymal / sarcomatous element:  
Composed of either homologous or heterologous elements 
                                    Homologous elements – 
                                                               undifferentiated sarcoma 
                                                               leiomyosarcoma 
                                                               endometrial stromal sarcoma 
                                    Heterologous elements - 
                                                             Malignant cartilage 
                                                             Malignant skeletal muscle /rhabdomyoblast 
                                                             Liposarcoma 
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                                                            Osteosarcoma 
 GESTATIONAL TROPHOBLASTIC DISEASE 
Disorders of  placental developement 
                          Hydatidiform mole  
                          Complete and Partial mole            
Neoplasms of Trophoblast 
                       Choriocarcinoma,  
                       Placental site trophoblastic tumor 
                       Epitheloid trophoblastic tumor 
A common feature of all these lesions is that they produce human chorionic 
gonodotrophin and it serves as a marker for persistent disease. 
 
 CHORIOCARCINOMA 
Gestational choriocarcinoma can occur following any type of  pregnancy 
Risk factor 
            Complete hydatidiform mole - major predisposing factor 
            Following abortion 
            Following term pregnancy   
The tumor arises from the trophoblastic tissue. 
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Presenting  features:    Abnormal vaginal bleeding in the postpartum period,   
Elevated serum hcG  
Microscopy: 
Absence of  chorionic villi,  
presence of dimorphic population of  trophoblastic cells. The syncytiotrophoblastic 
cells alternating with nest or sheets of  mononucleate cytotrophoblast or  intermediate 
trophoblast giving a plexiform pattern, invading the normal tissues. 
Hemorrhage and Necrosis are prominent. 
syncytiotrophoblast have eosinophilic  to amphophilic cytoplasm with small vacuoles 
or large lacunae that often contain RBCs. and have  multiple nuclei ranging from 3- 
20 per cell 
cytotrophoblast are small and uniform. They have a single nucleus and a prominent 
nucleoli. 
Intermediate Trophoblast:  large cells, polygonal  in shape, one or two large 
hyperchromatic nuclei occur in choriocarcinoma. 
IHC markers:   
ST: hCG + 
Inhibin- alpha+ 
PLACENTAL SITE TROPHOBLASTIC TUMOR: 
these tumors are usually  benign, despite destructive growth in the myometrium 
About 15% of reported tumors have shown aggressive malignant behavior with 
disseminated metastasis. 
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EPITHELOID TROPHOBLASTIC TUMOR: 
It is a rare tumor, recently recognized. They resemble the somatic carcinomas   
          
 IMMUNOHISTOCHEMISTRY ON UTERINE CORPUS 
MALIGNANCY 8 
no single marker is diagnostic to differentiate between endocervical and endometrial 
adenocarcinoma 
 Endometrial 
adenocarcinoma 
          UEC 
Endocervical 
adenocarcinoma ECA 
CEA Up to 50% 
Cytoplasmic,luminal, 
Intensity - strong 
100% 
Luminal 
Intensity - week 
Vimentin  +++       - 
ER Nuclear positivity  
PR Nuclear positivity  
P16 Diffuse 
Both nuclear and 
cytoplasmic 
Patchy 
 
international federation of gynecological and obstetrics FIGO  grades 1 and 2 uterine 
endometrial carcinomas tumors express ER ,PR and vimentin 
whereas most ECAs express CEA and P16 diffusely.  
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IMMUNOHISTOCHEMISTRY:  
Albert Coons et al in 1941 first labelled antibodies directly with fluorescent 
isocyanate. Nakane and Pierce et al in 1966, introduced the indirect labelling 
technique in which the unlabelled antibody is followed by second antibody or 
substrate. Various stages of development of Immunohistochemistry include 
peroxidase – antiperoxidase method (1970),  alkaline  phosphatase  labelling  (1971), 
avidin  biotin   method  
(1977) and two layer dextrin polymer technique (1993)40. 
ANTIGEN RETRIEVAL:  
Antigen retrieval can be done by the following different techniques to 
unmask the antigenic determinants of fixed tissue sections. 
1. Proteolytic enzyme digestion 
2. Microwave antigen retrieval 
3. Pressure cooker antigen retrieval 
4. Microwave and trypsin antigen retrieval 
PROTEOLYTIC ENZYME DIGESTION: 
Huank et al in 1976 introduced this technique to breakdown formalin cross 
linkages and to unmask the antigen determinants. The most commonly used enzymes 
include trypsin and proteinase41. The disadvantages include over digestion, under 
digestion and antigen destruction. 
MICROWAVE ANTIGEN RETRIEVAL: 
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This is a new technique most commonly used in current practice. Microwave oven 
heating involves boiling formalin fixed paraffin sections in various buffers for rapid 
and uniform heating.40 
 PRESSURE COOKER ANTIGEN RETRIEVAL: 
Miller et al in 1995 compared and proved that pressure cooking method   has 
fewer inconsistencies, less time consuming and can be used to retrieve large number 
of slides than in microwave method42. 
PITFALLS OF HEAT PRETREATMENT: 
Drying of sections at any stage after heat pre-treatment destroys antigenicity. 
Nuclear details are damaged in poorly fixed tissues. Fibers and fatty tissues tend to 
detach from slides while heating. Not all antigens are retrieved by heat pretreatment 
and also some antigens like PGP 9.5 show altered staining pattern. 
DETECTION SYSTEMS: 
After addition of specific antibodies to the antigens, next step is to visualize 
the antigen antibody reaction complex. The methods employed are direct and indirect 
methods.  
In the direct method, primary antibody is directly conjugated with the label. 
Most commonly used labels are flouro-chrome, horse radish peroxidase and alkaline 
phosphatase. Indirect method is a two-step method in which labelled secondary 
antibody reacts with primary antibody bound to specific antigen. The use of 
peroxidase enzyme complex  or  avidin biotin  complex  further  increases  the  
sensitivity of  
immunohistochemical stains40. 
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In 1993, Pluzek et al introduced enhanced polymer one step staining, in 
which large numbers of primary antibody and  peroxidase enzymes are attached to 
dextran polymer back bone. This is the rapid and sensitive method43. 
Dextran polymer conjugate two step visualization system is based on 
dextran technology in Epos system. This method has greater sensitivity and is less 
time consuming. 
USES OF IMMUNOHISTOCHEMISTRY IN LOWER UTERINE SEGMENT 
ADENOCARCINOMA: 
Distinction between endocervical adenocarcinoma of endometrioid type 
from endometrial adenocarcinoma of endometrioid type can be done using a panel of 
conventional immunohistochemical markers ER, PR, CEA,and VIMENTIN. 
other IHC markers found to be useful are P16, HPV ISH,ProExc.34  
The pre-operative distinction between an uterine adenocarcinoma and an 
endocervical adenocarcinoma is very important  because  the treatment for an 
endometrial cancer is commonly a simple hysterectomy (sometimes if the cervical 
involvement is identified before surgery , the treatment is modified radical 
hysterectomy) , while  for an endocervical adenocarcinoma primary chemotherapy is 
given with radical hysterectomy. 
                        
Figure 1. Tumour involving lower uterine segment and cervix arouse the 
suspicion of its primary 
Estrogenic Receptor  ER:
ER,  is an Estrogenic Receptor, which is  a protein of 67 kDa molecular 
weight, this  derives its name from the alpha estrogenic receptor. This estrogenic 
receptor gene composed of 140 kDa of DNA which is further divided into 8 exons,a  
C- terminus epitope, a SP1 clone and nuclear marker
Estrogen and progesterone receptors belong to super family proteins. These 
nuclear transcription factors are involved in breast development, growth and 
tumorigenesis.53 There are two forms of Estrogen receptors
Estrogen receptor β encoded by 6p25.1 and 14q genes respectively.
Estrogen receptor 
hypothalamus. Estrogen receptor 
Estrogen receptors regulate the expression of progesterone and bcl2.
Walker D et al in 1999 proposed that estrogen receptors are cytoplasmic in 
unliganded state. During activation, estrogen receptor diffuses into the cytoplasm and 
migrates to nucleus. After
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52
.  
 – Estrogen receptor 
53
  
α is found in endometrium, breast, ovarian stroma and 
β is seen in kidney,  brain, bone, heart and lungs. 
54
  
 dimerisation of the receptor, it binds to Hormone 
49 
α and 
50 
 
Responsive Elements in DNA and activate MAPK/P13K pathway to induce cell 
proliferation. 
ER immunoexpression  in the  paraffin blocks need a boiling pretreatment in 
10mMl citrate tampon, for a period of 20 minutes in  a  pH of 6.0 , and in the next 20 
minutes it is allowed to cool at room temperature . Then  the primary antibody is 
incubated into the tissues for next half an hour52 
A study showed, 93% of adenocarcinomas arising from endometrium with  
strong estrogen receptor (ER) positivity, while only 38% of endocervical 
adenocarcinomas  showing weak and focal ER positivity55. 
Progesterone Receptor PR: 
PR is a Progesteronic Receptor, which is a regulating protein  of the 
progesteronic receptor55. 
It  was  observed   that   PR   positivity  was  noted  in  81  %  of   
endometrial adenocarcinomas, while focal PR positivity noted in endocervical 
adenocarcinomas35. 
Along with ER expression , the PR expression appreciates not just the 
hormonal status of the tumour  but it also the effect of the treatment of patients using 
hormones52. 
PR expression is considered as a parameter depicting the prognosis. It has  
epitope 412-566aa, clone SP2, and  nuclear marker. 
PR immunoexpression  in the  paraffin blocks need a boiling pretreatment in 
10mMl citrate tampon, for a period of 20 minutes in  a  pH of 6.0 , and in the next 20 
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minutes it is allowed to cool at room temperature . Then  the primary antibody is 
incubated into the tissues for next half an hour52.   
ER and PR immunoreactivity take  positive staining reaction in endometrial 
adenocarcinoma and usually take negative staining in endocervical adenocarcinoma. 
Hence they are done commonly to exclude tumours having endocervical origin 53  
Carcinoembryonic antigen (CEA): 
CEA is a glycoprotein of heterogeneous composition , with the molecular 
weight of 200000. It is found in the  glycocalyx of epithelial cells of the fetus, 
especially in the epithelial lining of glands secreting  mucin44..It is identifiable in very 
small quantities in certain  benign tumors , and in normal cells of adults but in 
gastrointestinal adenocarcinoma , pancreatic adenocarcinoma, it is detected  in large 
amounts and also found in lung and in medullary carcinoma of thyroid.  
Because  of the fact that it is primarily expressed by fetal tissues  
and malignant tumors, it is referred to as an oncofetal antigen. Monoclonal antibodies 
are more specific than  the conventional antisera45. According to the epitopes  
recognized by them, they have been divided into five major groups46. 
It was found that the earliest identified immunophenotypic difference 
between cervical and endometrial adenocarcinoma was the increased frequency and 
intensity of staining of CEA immunoreactivity in cervical adenocarcinomas47, this  
observation is confirmed in multiple studies49. 
VIMENTIN: 
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Vimentin  is  the most  important  intermediate  filament  protein  of the 
tissues of mesenchymal origin . Vimentin  is one of the five major types of 
cytoplasmic intermediate filament (MW 57000). It is characteristic of  the cells of 
mesenchymal nature, such as , fibroblasts , endothelial cells, and vascular smooth 
muscle cells.48 Though it is characteristic of mesenchymal nature , it is not restricted 
to cells of mesodermal origin alone,  but it is  expressed in tumours of epithelial or 
neural nature also, not infrequently in conjunction  with keratin  and  GFAP,  
respectively.50 In the case of weakly differentiated neoplasms, this monoclonal 
antibody is used for the differential diagnosis. 
Actually, vimentin  is so ubiquitous  that  it  used  as    a control  of the  
immunohistochemical  reaction , in  the  sense of questioning its  reliability if there is 
no staining for vimentin in the tissue.  
Vimentin is usually  positive in  endometrial carcinomas (80%), and is positive in 
about 30% of ovarian endometrioid adenocarcinomas. In contrast, vimentin is 
negative or only focally positive in adenocarcinomas arising from the colon or 
endocervix51.  
P16INK4a 
p16INK4a gene is situated in the 9p21 chromosome which codes for a protein called a 
CDK4 and 6 which functions as a cell cycle inhibitor. It acts like a negative regulatory 
protein. 
In a normal quiescent cell, retinoblastoma protein is in a hypophosphorylated active 
state by binding it to a transcription factor E2F. It inhibits the action of the 
transcription factor thereby prevents the progression of cell cycle. Hence Rb is a 
negative regulator of  P16. 
53 
 
In  high risk HPV infected cell, the viral transcription factors gets bind to Rb protein 
and  make it inactive, so Rb protein cannot be able to inhibit the transcription of P16 
tumor suppressor protein. Thus P16 is over expressed in dysplastic cells but not in 
normal cells. 
identification of biomarker P16 by IHC in dysplastic cells in cervical cancer is an 
ongoing study all over the world14 . 
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IMMUNOHISTOCHEMISTRY SCORING SYSTEM 39 : 
Estrogen receptor staining are scored using 3 scoring system namely 
 
1. ALLRED SCORING SYSTEM 
2. H- SCORE 
3. ASCOP/CAP SCORE 
Allred scoring system: 
Allred  scoring system stratifies the carcinoma in to the cancers that are likely to 
respond to hormone therapy . 
The score was given based on the percentage of proportion of cells taken the stain and 
the intensity of  the stain 
Proportion of tumor 
cells taken nuclear 
stain  
 Score 
No cells taken 0 
<1% 1 
1-10% 2 
11-33% 3 
34-66% 4 
67-100% 5 
 
Intensity of the stain – 
ER 
SCORE 
No staining 0 
Weak 1 
Intermediate 2 
Strong 3 
 
 
ALLRED SCOREING FOR ER INTERPRETATION : 
It’s the sum of proportion score and intensity score 
0-2 = negative 
3-8 = positive 
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ALLRED SCORING BENEFITS IN BREAST CANCER 
 
 
 
 
 
 
H-SCORE: 
IT assess the extent of nuclear immunoreactivity applicable to steroid receptors 
The score is obtained by the formula 
3 x % of strongly staining nuclei + 2 x % moderately staining nuclei + % of weakly 
staining nuclei. 
Range = 0-300 
 
ASCOP/CAP: 
American society of cancer oncology/ college of American pathologist guidelines: 
Tumors with 1-10% of the ER staining would be classified as ER positive. 
In terms of prognostic value , ASCOP/CAP Scoring system is better compared to 
Allred scoring  
P16- SCORING: 
Tumor was given a score  according to the intensity of nuclear or cytoplasmic staining 
and extent of stained cells. 
Intensity of nuclear 
staining 
Score 
No staining 0 
Weak staining 1 
Moderate staining 2 
Strong staining 3 
 
Extent of stained cells Score 
No staining 0 
1-10% of cells  1 
11-50% 2 
51-80% 3 
81-100% 4 
 
SCORE Chance of benefit with 
hormone therapy. 
0-1 No benefit 
2-3 Small (20%)  
4-6 Moderate (50%) 
7-8 Good (75%) 
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The final score was determined by multiplying the intensity and extent of positivity 
score of stained cells 
Score = Intensity X Extent 
Minimum score = 0 
Maximum score = 12 
Optimal cut off value of 4 
                4 or more - positive  
                0 - 3    -  negative 
IHC based on independent nuclear staining can sufficiently distinguish between 
endometrial and endocervical adenocarcinoma 
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                                                                                                                  MASTER CHART 
S.NO  HPE-
NO 
IP-NO AGE PROVISIONAL 
DIAGNOSIS 
Sp GROSS FINAL DIAGNOSIS VARIANT
1. G189/
12 
238975 55 CA ENDOMETRIUM 1  ENDOMETRIAL AC ENDOMETRIOD
2. G276/
12 
195325 61 CA ENDOMETRIUM 1  ENDOMETRIAL AC ENDOMETRIOD
3. G1200
/12 
204428 62 CA ENDOMETRIUM 3 Ragged, PE  ENDOMETRIAL AC ENDOMETROID
4. G1806
/12 
4198 42 FIBROID UTERUS 3 Ragged PE ENDOMETRIAL AC ENDOMETRIOD
5. 1960/
12 
private 55 PYOMETRA 2 Cystic, PE ENOMETRIAL SCC SARCOMATOID 
6. G2769
/12 
JAYAM GH 55 ADENOMYOSIS 
UTERUS 
3 Ragged, PE ENDOMETRIAL AC ENDOMETRIOD
7. G2809
/12 
219187 47 ?CA 
ENDOMETRIUM 
1  ENDOMETRIAL AC ENDOMETRIOD
8. G3333
/12 
224779 47 CA ENDOMETRIUM 4  Ragged, PE ENDOMERIAL  
AC 
ENDOMETRIOD
9. G3502
/12 
225057 40 ENDOCERVICAL 
POYP 
1 Polypoid ENDOMETRIAL 
STROMAL SARCOMA 
 
10. G4056
/12 
232013 52 CA ENDOMETRIUM 2 Ragged, PE ENDOMETRIAL AC ENDOMETRIOD
11. G4297
/12 
234133 62 ENDOMETRIAL CA 1  ENDOMETRIAL AC SEROUS PAPILLARY
(UPSC)
12. G4677
/12 
238975 47 ENDOMETRIAL 
CA 
1  ENDOMETRIAL CA ENDOMETRIOD 
villoglandular
13. G82/1
3 
247407 60 ENDOMETRIAL CA 2 Ragged, PE ENDOMETRIAL AC ENDOMETRIOD
14. G84/1
3 
247407 44 ENDOMETRIAL 
CA 
3 Ragged, PE ENDOMETRIAL AC ENDOMETRIOD
NOS
15. G268/ private 68  3 Ragged, PE ENDOMETRIAL AC SEROUS PAPILLARY
 
OBSERVATION AND RESULTS 
                    The  current study was carried out from January 2012 till June 2015 for a 
period of three and half years. 
                     Totally we have received 7910 gynaecological specimens for 
histopathological examination. Out of which 761 cases are reported as uterine corpus 
neoplasm’s including benign and malignant neoplasms. This constitutes for 9.6 % of 
cases excluding Cervical, ovarian, and adnexal neoplasms. 
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Table 1.  Illustration of the total no of Uterine Corpus Neoplasms and its 
incidence year wise data. 
  
Total no of  
Specimens 
received 
 
Benign 
neoplasm 
 
Malignant 
neoplasm 
 
No of uterine 
corpus 
neoplasms 
 
Incidence 
per year 
2012 
Jan- Dec 
5091 358 12 370 7.2% 
2013 
Jan-Dec 
1199 153 19 172 14.3% 
2014 
Jan- Dec 
1155 132 19 151 13.07% 
 Till June 
2015  
465 58 10 68 12.47% 
 7910 701 60 761 
(7910/761=9.6) 
9.6%  in 
3.5 yrs   
 
CHART NO: 1A 
TOTAL NO OF GYNECOLOGICAL SPECIMENS RECEIVED IN THREE AND 
HALF YEARS PERIOD 
CHART NO: 1B - TOTAL 
 From this 761 uterine corpus 
period, 60 cases were reported as malignant tumors,  hence  the overall incidence of 
uterine corpus malignancies in this given period is 
documented within this period from
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 Endometrial carcinomas,  
 Endometrial stromal sarcomas,  
 Leiomyosarcoma,  
 Choriocarcinoma 
 Carcinosarcoma.  
 Germ cell neoplasm.                                                    
Table.2  & chart -2 Distribution of uterine corpus malignancies based on 
the histological type. 
                 
   Out of 60 cases of uterine corpus malignancies , 49 cases of endometrial 
carcinomas, 4 cases of choriocarcinoma, 4 cases of leiomyosarcoma and single case 
of endometrial stromal tumor, carcinosarcoma, germ cell neoplasm- yolk sac tumor 
each received. 
                 UTERINE CORPUS MALIGNANCIES YEAR WISE DATA 
Malignant cases 
reported in TMC 
2012 2013 2014 2015 Total   
    % 
Endometrial ca 11 13 17 8 49 81.6% 
Endometrial 
stromal sarcoma 
1 - - - 1 1.6% 
Leiomyosarcoma - 1 2 1 4 6.6% 
Choriocarcinoma 0 3 - 1 4 6.6% 
Germ cell tumors - 1 - - 1 1.6% 
Carcinosarcoma - 1 - - 1 1.6% 
Total 12 19 19 10 60/761=7.8%  
The incidence of uterine corpus malignancies in the given period  is 7.8%  
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                  It has  been observed  that predominant of the cases are arising from 
endometrial surface epithelial cells, i.e. endometrial carcinomas which constitutes for  
81.6%  of the total uterine corpus malignancy, followed by leiomyosarcoma 6.6% and 
choriocarcinomas of about 6.6% of cases.  Other tumors such as endometrial stromal 
sarcoma,  carcinosarcoma, germ cell neoplasm, yolk sac tumor carry the same 
incidence of about 1.66%.  
Observation and analysis of individual uterine corpus malignancies: 
Endometrial carcinomas:  
This is the most common malignancy observed in our study. Out of 60 cases 49 cases 
are of Endometrial carcinoma which constitutes about 81.6% of cases. 
Based on World health organization (WHO) classification of endometrial 
adenocarcinoma, there are about nine different differentiation of adenocarcinomas 
known to arise from endometrium. In our study five types of adenocarcinoma is 
noted.  
Different histologic types and numbers of endometrial carcinoma has been 
documented as shown  in  Table no 3 , 42 cases of endometriod adenocarcinoma, 3 
cases of uterine papillary serous adenocarcinoma, 2 case of poorly or undifferentiated 
carcinoma and single case of clear cell adenocarcinoma and squamous cell carcinoma 
each have been recorded. 
CHART NO:2A 
CHART NO: 2B DISTRIBUTION OF ENDOMETRIAL CARCINOMAS
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TABLE NO: 3 & CHART : 3 - DIFFERENT HISTOLOGIC TYPES OF 
ENDOMETRIAL CARCINOMAS 
 
                                                                                                                                                                         
Among all the type, endometroid endometrial adenocarcinoma  being the most 
common pattern noted which constitutes about 85% of cases , followed by uterine 
papillary serous adenocarcinoma of about 6% , undifferentiated or poorly 
differentiated tumor of 4.08% and 2.04% of  clear cell adenocarcinoma and squamous 
cell carcinoma each 
Different patterns of endometrial  adenocarcinoma  
There are about 33 number of cases exhibiting endometriod NOS type pattern, 5 cases 
exhibiting endometriod carcinoma with squamous metaplasia, and four cases with 
villoglandular pattern in out of total 42 cases of endometriod endometrial 
adenocarcinoma 
HISTOLOGICAL TYPES OF ENDOMETRIAL ADENOCARCINOMAS 
IN 49/60  CASES 
 Endometroid 
adenocarcinomas 
42 85.7% 
UPSC   6.1% 
Clear cell adenocarcinoma 1 2.04% 
Squamous cell carcinoma 1 2.04% 
Poorly differentiated 
carcinoma 
2 4.08% 
. CHART: 3A 
CHART:3B 
 
The most common pattern observed from the  received specimens 
not otherwise specified type which constitutes about  76.7
Endometroid adenocarcinomas
UPSC
Clear cell adenocarcinoma
Squamous cell carcinoma
Poorly differentiated carcinoma
Endometroid 
adenocarcinomas
Series1 42
HISTOLOGICAL TYPES OF ENDOMETRIAL 
6%
2% 2%
HISTOLOGICAL TYPES OFENDOMETRIAL 
ADENOCARCINOMAS
 are endometriod  
%.  
0 5 10 15 20 25 30
UPSC
Clear cell 
adenocarcinoma
Squamous cell 
carcinoma
3 1 1
ADENOCARCINOMAS
86%
4%
Vs PERCENTAGE
Endometroid adenocarcinomas
UPSC
Clear cell adenocarcinoma
Squamous cell carcinoma
Poorly differentiated carcinoma
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Poorly 
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carcinoma
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Followed by adenocarcinoma with squamous metaplasia 11% and  villoglandular 
pattern 9.3%. 
Table 4 & chart : 4-  Illustrations of different patterns of endometrial 
adenocarcinoma 
 
GRADING OF ENDOMETRIAL ADENOCARCINOMAS. 
In our study the tumors are graded in to I, II, III, for endometriod adenocarcinomas. 
Others tumors such as uterine serous papillary adenocarcinoma, clear cell carcinoma 
and squamous cell carcinomas are graded as high grade tumors which carries the 
same poor prognosis as the grade III carcinomas as per WHO. 
Based on the data collected within this three and half years period 37 cases fall under 
grade I tumors, 3 cases are of gradeII, four cases of Grade III and we have received  3 
cases of uterine serous papillary adenocarcinoma, 1 case of clear cell 
adenocarcinoma, and one case of squamous cell carcinoma which all grouped in high 
grade tumors. Hence a total of 5 case of high grade malignant neoplasms documented 
here.  
This corresponds to 75.5% of grade 1 tumors, 6.1 % of grade II tumors, 8.16 % of 
grade III tumors and 10.2% of high grade tumors as shown in table 5 & Chart 5. 
 
          Endometriod endometrial adenocarcinoma variants: 42/60 cases 
Endometriod NOS 33 76.7% 
Villoglandular type 4 9.30% 
Endometriod with squamous metaplasia 5 11.6% 
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Table -5 &  chart-5 : Grading of endometrial adenocarcinoma  
STAGING OF ENDOMETRIAL ADENOCARCINOMAS: 
Table -6 & chart-6  : staging of endometrial carcinoma 
Staging by AJCC 
in  Hysterectomy 
specimen with 
Endometrial carcinoma 
cases 
 
 
Total no of cases   
(25) 
 
 
Percentage  
PT1aN0M0/ stage IA 13 52% Stage I 
                80% PT1bN0M0/ stage IB 7 28% 
PT2NoM0/ stage II 3 12% Stage II 
12% 
PT3aN0M0/ stage IIIA 1 4%            Stage III 
                8% PT3bN1M0/ stage 
IIIC1 
1 4% 
  Out of 49 cases of endometrial carcinomas , 25 cases are hysterectomy specimens, 
the rest all are small biopsy/curettage specimen. From the 25 hysterectomy specimen 
with endometrial carcinomas  staging was done  based on FIGO’s classification. 
 
 
       Endometrial carcinoma   
 
              Total 49 cases 
Grading 
  
Grade I 37 75.5% 
Grade II 3 6.1% 
Grade III 4 04 % 
HIGH GRADE ( UPSC & clear 
cell , squamous cell carcinoma) 
5 10.2% 
CHART: 4 
 
CHART 5 
 
 According to that 13 cases are  in stage IA , 7 cases are IB, 3 cases fall in stage II, 1 
case of stage III a and C1, which corresponds to 52% of  stage IA, 28% of stage IB, 
12% of Stage II cases and 4 % each of stage IIIA and stage III C1. To su
stage I cases constitutes about 
GROSS PRESENTATION OF ENDOMETRIAL ADENOCARCINOMA
Majority of the cases presented as irregular ragged ,papillary growth filling the 
endometrial cavity and three cases pr
the myometrium. 
 
9%
Endometriod endometrial adenocarcinoma 
mmarize 
 80%, stages II cases of 12%, stage III of 8 %.
esented as polypoid growth yet infiltrating in to 
79%
12%
variants: 42/60 cases
Endometriod NOS
Villoglandular type
Endometriod with squamous 
metaplasia
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IIIC1
1
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One case of squamous cell carcinoma of endometrium classically presented with cytic 
lesion  with prior history of pyometra in an elderly women. 
here  84% of endometrial adenocarcinoma cases presented as irregular, ragged , 
friable papillary growth, 12% of cases as polypoid and 4% as cystic  as shown in table 
no-7 
Table no :7 & chart no:7-  illustration of gross presentation of endometrial  
carcinoma 
  
 
 
 
Age 
distribution of endometrial adenocarcinomas:     
CHART : 7 
 
                     ENDOMETRIAL CARCINOMA - GROSS  
                            25 HYSTERECTOMY SPECIMENS 
Irregular, ragged endometrium 21 84% 
Polypoid 03 12% 
Cystic 1 4% 
  
 
 
 
 
 
 
 
 
 
 
 
ENDOMETRIAL CARCINOMA 
Irregular, ragged endometrium
84%
12%
4%
- GROSS 
Polypoid Cystic
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Table no: 8 & chart 8 
AGE GRADE I GRADE II GRADE III HIGH 
GRADE 
  
20 – 29        --           --            -          --     0 0% 
30 – 39       01          01           --         --     02 4.08% 
40 – 49       11          01           01          --     13 26.5% 
50 – 59       19           --           03        01     23 46.9% 
60 – 69       05          --            --        03     08 16.3% 
70 – 80      01           01            --        01     03 6.1% 
Total : 49        37           03            04        05     49 100% 
percentage     75.5%         6.12%         8.16%      10.2%   
 
TABLE 9 & CHART 9 : AGE DISTRIBUTION IN ENDOMETRIOD 
ADENOCARCINOMA 
ENDOMETRIOD TYPE ENDOMETRIAL ADENOCARCINOMAS IN 42 CASES 
AGE GRADE I GRADE II GRADE III   
20 – 29        --           --            -  0 0% 
30 – 39       01          01           -- 02 4.7% 
40 – 49       11          01           00 12 28.5% 
50 – 59       19           --           02 21 50% 
60 – 69       05          --            -- 05 11.9% 
70 – 80      01           01            -- 02 4.7% 
From the data analysed for the age parameter 
endometrial adenocarcinoma seems to appear more between 
CHART NO: 8A 
CHART NO: 8B 
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and well differentiated grade I adenocarcinoma is prevailing high  in between 50 -60 
years   
LEIOMYOSARCOMA DATA ANALYSIS  
LEIOMYOSARCOMA AGE GROSS SIZE GRADE 
G1157/13 38 IM, Fairly circumscribed 
mass 
13 cm Low grade 
G946/14 32 IM, fairly circumscribed 6X6 cm Low grade 
G788/14 55 Intra mural mass 10x7 High grade 
G378/15 40 Intramural mass 9x9 cm Low grade. 
 
                   All the cases of leiomyosarcoma reported in our institution presented as  
fairly circumscribed intramural mass with an average size of 9.5 cm. The median age 
group of presentation is 39 years. 75 % tumors are in lowgrade with epitheloid 
differentiation. The incidence being 6.6% in our study.   
CHORIOCARCINOMA 
This is the next common malignant tumor observed following endometrial 
adenocarcinoma and leiomyosarcoma. totally 4 cases have been documented in this 
given period all fall within the age group between 2nd and 3rd decade. it carries the 
same incidence of 6.6% as that of leiomyosarcoma. 
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ENDOMETRIAL STROMAL SARCOMA 
one case of endometrial stromal sarcoma has been reported in our study in a 40 years 
old lady presenting as a polyp. It constitutes 1.65% of uterine malignant neoplasm in 
this current study. 
CARCINOSARCOMA 
one case of carcinosarcoma has been reported in a 44 years old lady presenting as an 
intramural mass with homologous differentiation. It also carries a 1.6% incidence in 
our study. 
GERM CELL NEOPLASM: 
a rare case of yolk sac tumor in the endometrium is noted. This  germ cell neoplasm 
was diagnosed in a 19 year old girl presenting like a sarcoma uterus. 
Histopathological examination revealed a classic schiller dual bodies and the pattern. 
Its incidence is 1.6% in our study in the given period of time. 
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USE OF IMMUNOHISTOCHEMISTRY TO DISTINGUISH ENDOMETRIAL 
ADENOCARCINOMA VERSUS ENDOCERVICAL ADENOCARCINOMA. 
We applied IHC markers  ER and P16 antibody on 20 biopsy specimen which 
includes 10 cases, reported as endometrial adenocarcinoma and 10 cases reported as  
endocervical adenocarcinomas in our institution. 
We Analysed the intensity and proportion of staining to give a positive or negative 
staining report and correlated with the HPE report. 
IMMUNOHISTOCHEMISTRY INTERPRETATION 
Estrogen receptor scoring was done using ALLRED SCORING SYSTEM 
Allred scoring system: 
The score was given based on the percentage of proportion of cells taken the stain and 
the intensity of  the stain 
Allred score = 
 proportion of cells  taken  nuclear stain +  in score and intensity score 
 
Proportion of tumor cells 
taken nuclear stain  
  
Score 
No cells taken 0 
<1% 1 
1-10% 2 
11-33% 3 
34-66% 4 
67-100% 5 
 
Intensity of the stain – ER 
 
SCORE 
No staining 0 
Weak 1 
Intermediate 2 
Strong 3 
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maximum score =8 
minimum score = 0 
 Results    ≤ 2 = negative 
                 3-8 = positive 
P16- SCORING: 
Tumor was given a score  according to the intensity of nuclear sating 
 and extent of stained cells. 
Intensity of nuclear 
sating 
Score 
No staining 0 
Weak sating 1 
Moderate staining 2 
Strong staining 3 
 
 P16 SCORE=  Intensity  of the stain X Extent of positivity  
maximum score = 12 
minimum score = 0 
RESULT: 
≤ 4 : negative≥ 4 : positive  
 
 
Extent of stained cells Score 
No staining 0 
1-10% of cells  1 
11-50% 2 
51-80% 3 
81-100% 4 
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S.NO 
 
 
 
 
HPE no 
 
 
 
HPE 
REPORT 
 
           
 
  Estrogens receptor - ER 
 
             (ALLRED SCORE) 
  
                                    
                          P16 
INTEN
SITY 
 
EXTE
NT 
R= I + E 
0-2 =   NEG 
2-8 =   POS 
INTENSITY 
     ( I ) 
EXTENT 
    (E) 
 R=IxE 
<4-  neg 
>4 – POS 
Cases reported as endocervical adenocarcinoma 
1. P823/15 EC AC 0 0 0 NEG  3 4 12 POS 
2. P645/15 EC AC 0 0 0 NEG 3 4 12 POS 
3. P522/15 EC AC 2 3 5 POS 3 4 12 POS 
4. P697/15 EC AC 0 0 0 NEG 1 4 3 NEG 
5. P3090/14 EC AC 0 0 0 NEG 3 4 12 POS 
6. P598/14 EC AC 1 3 4 POS 3 4 12 POS 
7. P2915/13 EC AC 0 0 0 NEG 3 4 12 POS 
8. P2697/13 EC AC 0 0 0 NEG 3 3 9 POS 
9. P2429/13 EC AC 1 3 4 POS 3 4 12 POS 
10. P625/13 EC AC 0 0 0 NEG 3 4 12 POS 
Cases reported as endometrial adenocarcinoma 
1. P78/14 EM AC 0 0 0 NEG  2 3 6 POS 
2. G1091A/13 EM AC 3 5 8 POS 2 1 2 NEG 
3. P1300/14 EM AC 3 5 8 POS 1 2 2 NEG 
4. P2438/14 EM AC 3 5 8 POS 2 1 4 NEG 
5. P152A/15 EM AC 3 5 8 POS 2 1 2 NEG 
6. P256/15 EM AC  3 5 8 POS 2 1 2 NEG 
7. P377/15 EM AC 3 5 8 POS 1 3 3 NEG 
8. P550/15 EM AC 0 0 0 NEG 3 4 12 POS 
9 G11C/14 EM AC 0 0 0 NEG 2 3 6 POS 
10. p554/14 EM AC 0 0 0 NEG 3 4 12 POS 
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EMAC: Endometrial adenocarcinoma 
ECAC: Endocervical adenocarcinoma 
INFERENCE 
IP NO AGE GRADE DIAGNOSIS ER P16 
P823/15 37 WD  EC AC NEG POS 
P645/15 35 WD -VG EC AC NEG POS 
P522/15 47 WD EC AC POS POS 
P697/15 60 WD EC AC NEG NEG 
P3090/14 52 WD EC AC NEG POS 
P598/14 41 WD-VG EC AC POS POS 
P2915/13 45 WD EC AC NEG POS 
P2697/13 57 WD EC AC NEG POS 
P2429/13 75 WD EC AC POS POS 
P625/13 62 WD-VG EC AC NEG POS 
IP NO AGE Diagnosis  Grading  ER P16 
P78/14 50 EM AC Grade-1 NEG POS 
G1091A/13 57 EM AC Grade-1 POS NEG 
P1300/14 54 EM AC Grad-1 POS NEG 
P2438/14 65 EM AC Grade-1 POS NEG 
P152A/15 50 EM AC Grade-1 POS NEG 
P256/15 75 EM AC  Grade-2 POS NEG 
P377/15 38 EM AC Grade-2 POS NEG 
P550/15 47 EM AC Grade-1 NEG POS 
G11C/14 70 EM AC Grade-3 NEG POS 
p554/14 50 EM AC Grade-1 NEG POS 
ENDOCERVICAL 
ADENOCARCINOMA 
 
       ER 
    
        % 
 
P16 
 
     % 
80 
 
 
 
 
                         In our study,  out of  10 cases of endometrial adenocarcinoma, 6 cases 
showed positivity for  ER which constitutes 60% positivity and out of 10 cases of 
endocervical adenocarcinoma 3 cases showed positivity i.e. about 30% of cases.   
out of 10 endocervical adenocarcinomas 90% cases showed P16 positivity and in 10 
cases of endometrial adenocarcinoma  40 % cases showed positivity. 
out of 20 cases three cases showed both marker positivity 24.3% and one case was 
negative for both markers i.e. 5 % showed negativity for both markers 
ASSOCIATION OF TUMOR GRADE WITH ER EXPRESSION 
GRADE     ER POSITIVE  ER NEGATIVE 
POSITIVE     3/10       30 % 9/10     90% 
NEGATIVE     7/10       70 % 1/10      10% 
BOTH POSITIVE              3 
BOTH NEGATIVE              1 
ENDOMETRIAL 
ADENOCARCINOMA 
 
       ER 
 
       % 
 
P16 
 
    % 
POSITIVE       6/10         60 % 4/10   40% 
NEGATIVE       4/10         40% 6/10    60% 
BOTH POSITIVE                 0 
BOTH NEGATIVE                 0 
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Grade  I               4          3 
Grade  II               2           0 
Grade III               1            0 
.   
Total the chi square statistics is 2.857,the P value is 0.23965 the result is not 
significant as it is more than 0.05. 
  
 
 
 
 
 
 
 
 
 
 
                                                    DISCUSSION 
                          Gynaecological cancers have increased in India and are estimated to 
be around 30 % of total cancer by 2020 among women in india1  
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uterine corpus malignancies constitutes the third  most common site of cancer in 
female genital tract following cervix and ovarian neoplasm  in our country and other 
developing countries, where as in developed countries endometrial carcinoma is the 
most common  gynaecological malignancy reported. 
                            This study was conducted with the objective of assessing the 
incidence and histopathological analysis of uterine corpus malignancies in Thanjavur 
medical college in a given period of three and half years from January 2012 till June 
2015. The  second objective is to distinguish endometrial adenocarcinoma from 
endocervical adenocarcinoma in a biopsy/curetting  specimen  using 
immunohistochemical marker ER and P16 . 
                             In the given study period we have received 7910 cases  out of which 
761 cases are uterine corpus neoplasms  comprising both 701 cases of benign and 60 
cases of malignant neoplasm. This constitutes for  9.6% of cases of uterine corpus 
neoplasm. 
                            Histopathologic analysis of  uterine corpus malignancies  was done 
on all 60 cases in total and compared with other literatures and journals in relation to 
incidence, age,  presentation, grading, and staging of tumors .  
                          The most common malignant tumor observed in our study is 
Endometrial carcinoma which constitutes about 82 %, followed by choriocarcinoma 
and leiomyosarcoma carrying the same percentage of 7% each. Other malignant 
tumor observed within this period are  Endometrial stromal sarcoma,  Carcinosarcoma 
and Germ cell neoplasm  2% each. Giving a incidence of uterine corpus malignancies 
in the given period about 7.8% 
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TABLE: 1 PERCENTAGE OF ADENOCARCINOMA  OF UTERINE CORPUS IN 
OTHER STUDIES 
     
 
 
 
 
 
 
                                         In comparison with other studies among uterine corpus 
malignancies, Endometrial adenocarcinoma is the most common malignant neoplasm 
observed  in all studies with overall percentage above 80% as shown in the table 
no:1.this is in concordance with the present study. 
In a large study conducted by carol L kosary20  out of  48600 cases, 44059 cases are 
of endometrial  adenocarcinoma that constitues about 90.6%. 
Study conducted by kathryn m greven et al33 and  Pavlo et al11 study shows a closer 
percentage of endometrial adenocarcinoma as in our current study . 
According to the SEER fact sheet20  the estimated  new cases of endometrial 
carcinoma  in 2015 is 54870, the percentage of all new endometrial cancer cases is  
 
 
 
 
Endometrial adenocarcinoma            Percentage 
Kathryn m.greven et al33               85%  
Paola A.Gehrig et al11               80% 
Carol L Kosary 20 SEER statistics.               90.6%      
F.Gholipour et al 21              70.5% 
Current study                82% 
CHART:1 PERCENTAGE OF ADENOCARCINOMA OF UTERINE 
 
 
CHART 1B: PERCENTAGE OF ENDOMETRIO
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 3.3% and the estimated death in 2015 is 10170. percentage of all cancer deaths is 
1.7%. percent age of people affected  surviving in 5 years  is  81.7%  
ADENOCARCINOMA OF UTERINE  CORPUS : DISTRIBUTION BY 
HISTOLOGY  
TABLE:2 COMPARISON OF HISTOLOGICAL TYPES 
                               In comparison with other studies done by Carol.L.karosky20 and 
G.plataniotis22 Endometriod adenocarcinomas is the most common type with a mean 
percentage of 81% followed by next highest adenocarcinoma being uterine papillary 
serous adenocarcinoma with a mean of 5.6% and clear cell carcinoma with a mean 
incidence of 1.8%. 
The other  histologic type mentioned in other studies are not compared in our 
discussion. 
HISTOLOGICAL TYPES 
OF ENDOMETRIAL 
ADENOCARCINOMAS 
 
current 
study 
 
Coral.L.Karosky20 
 
G.plataniotis22 
et al 
 Endometroid 
adenocarcinomas 
85.7% 83% 75% 
UPSC 6.1%            5.8%            5% 
Clear cell adenocarcinoma 2.04%           1.6%            2% 
Poorly differentiated 
carcinoma 
4.08%         -             - 
Squamous cell 
differentiation 
2.04%           1.9%          1% 
CHART: 2 COMPARISION OF HISTOLOGICAL TYPES
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Endometroid 
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Poorly differentiated 
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Squamous cell 
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DIFFERENT PATTERNS OF ENDOMETRIAL ADENOCARCINOMA: 
                77 % of endometrial adenocarcinoma exhibited endometrioid NOS type 
followed by villoglandular pattern 10% and endometrioid with squamous metaplasia  
of 12%.  
TABLE NO : 3 : GRADING OF ENDOMETRIAL ADENOCARCINOMAS 
 
                               Grade II  tumors are more common in endometrial 
adenocarcinomas , as shown  in the table no:3 which  is not in concordance with our 
study where Grade I tumors are more common. 
                from the study conducted by Behiye etal23,  in a total of 335 patients ,152 
cases were of grade 2 (45.4%) and 40.9% & 13.7% of them had grade 1 and grade 3 
disease 
                   paola et al11 out of 55 cases evaluated 13 had grade I (23.6%), 24 had 
grade 2(43.6%), 18 had grade 3 tumors (32.8%) 
                     The study conducted by Geisher JP et al 25, showed that none of the 
grade I tumors had lymphnode metastasis , which is also observed in our study. The  
 
Grading 
 
Current study  Behiye etal23 Geisher Jp et 
al25 
Paola et al11 
Grade I 75.5% 40.9% 38% 23.6% 
Grade II 6.1% 45.4% 47.6% 43.6% 
Grade III 04 % 13.7% 13.8% 32.8% 
CHART NO: 3 GRADING OF ENDOMETRIAL ADENOCARCINOMAS
 
 
 
 
 
former study  concludes that pelvic and paraaortic node dissection is not required for 
grade I tumors. It should be reserved for grade 2 tumors and above.
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TABLE : 4; UTERINE CANCER  INCIDENCE BY STAGE: 
 
 
 
In our study 80 % of patients presented in stage I disease  which is in close range with 
SEER statistics showing 75 % of patients presenting in stage I disease. where as in 
STAGING  Percentage 
 
current study 
 
 Uterine 
Cancer 
Statistics 
Uk 
2012 
SEER 
statistics 
 
Behiye et 
al23 
Paola et al 
PT1aN0M0/ stage IA 52% Stage I 
      80% 
 
57% 
 
75.3% 
 
80.2% 
 
65.5% 
PT1bN0M0/ stage IB 28% 
PT2NoM0/ stage II 12% Stage II 
12% 
 
5.1 % 
 
7.9% 
 
6% 
 
14.5% 
PT3aN0M0/ stage IIIA 4%  Stage III 
       8% 
            
          
7.8% 
 
       6% 
 
      9% 
 
    
 
      11% 
PT3bN1M0/ stage 
IIIC1 
4% 
STAGE  IV 0% STAGE IV 4% 7.5% 4.8% 
STAGE NOT 
KNOWN  
0% STAGE 
NOT 
KNOWN 
24.5% 3.3% -  
90 
 
UK cancer statistics data shows 57 % patient presenting in stage I disease and 66% in 
Paola et al11 studies, 
                    Most of the cases of endometrial carcinoma are diagnosed earlier because 
of the symptom  of abnormal vaginal bleeding, the patient will seek medical consult 
and diagnosed earlier. 
                   Only less percentage of cases reach stage IV as more common  with the 
case of  uterine serous papillary carcinoma  of endometrial  because of the tumor 
arising from atrophic endometrium and does not  follow endometrial hyperplasia 
sequence hence they develop symptoms late present in advanced stages. 
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ADENOCARCINOMA AGE AND STAGE COMPARISON 
                                    When  age and stage variables are compared 70 % of cases 
were diagnosed within the age  range from 50- 69 years of age. This almost goes 
similar with the study conducted by carol L kosary20. 
Across all age groups 70 % or more of all cancers were diagnosed in stage I. 
which goes in concordance with  the literature that  endometrial adenocarcinoma 
usually diagnosed earlier and hence the prognosis is better. 
TABLE NO:5 
                                               Age in years 
AJCC 
stage 
Carol L  Current 
study 
Carol L Current 
study 
Caro L Current 
study 
 
               20-49 yrs                  50-69 yrs              70+ yrs 
Stage I 77.1 100 % 78.2 % 73.6 % 70.2% - 
Stage II 8.1%  - 7.0% 10.5% 6.8% - 
Stage III 5.9% - 5.5% 15.7% 9.2% - 
Stage IV 5.5% - 2.4% - 4.8% - 
Unknown 
/unstaged 
3.0% -  -  - 
 
In our current study majority of the uterine corpus neoplasms presented in grade I 
disease. with the median age of presentation of 51 years and with a mean age of 52.5 
years. 
inference of uterine cancer incidence by age: 
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INCIDENCE OF UTERINE SARCOMAS 
                               In our study out of 60 cases of corpus uterine malignant 
neoplasms, uterine sarcomas constitutes about 9.8 %;  which includes 66% of 
leiomyosarcoma, 16% of Endometrial stromal sarcoma and 16% of carcinosarcoma. 
In the study conducted by carol l kosary20, the incidence of uterine sarcoma is 7.7%  
which comprised of 34% of mullerian, 25 % of leiomyosarcoma ,19% of 
carcinosarcoma, and 16 % of carcinosarcoma. when compared to our study. the 
sarcoma incidence is 9.8%  
TABLE NO: 6 
 
 
 
 
 
 
 
In our study leiomyosarcoma carries higher incidence than endometrial stromal 
sarcoma as compared with carol L Kosary study   
 
 
 
 
 Uterine Sarcoma 
incidence  
Current 
study 
Carol 
L.kosary. 
Total  9.8% 7.7% 
Leiomyosarcoma   66% 25% 
Endometrial 
stromal sarcoma 
 16% 34% 
Carcinosarcoma 16% 16% 
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EVALUATION OF IMMUNOHISTOCHEMICAL MARKERS ER AND P16 
EXPRESSION IN ENDOMETRIAL ADENOCARCINOMA AND 
ENDOCERVICAL ADENOCARCINOMA CASES IN BIOPSY/CURETTINGS 
SPECIMEN. 
 
TABLE NO-7A:COMPARISON OF ER EXPRESSION IN  WELL 
DIFFRENTIATED ENDOMETRIAL ( GRADE I) ADENOCARCINOMA : 
STUDIES ER POSITIVE 
McCluggage et al12                 93% 
Staebler et al 27                 75% 
Paola A.Gehrig et al 11                 87.3% 
Sophia Kounelis et al 16                  54% 
Current study                  60% 
  
Mccluggage et al evaluated 30 endometrial adenocarcinoma and 26 endocervical 
adenocarcinomas, in their study 93% were strongly positive forER. 
staebler et al studied 24 endometrial and 24 endocervical adenocarcinomas found that 
75% expressed ER. 
 Paola et al studied out of 55 endometrial adenocarcinoma 48 tumors were ER 
positive(87.3%) 
sophia Kounelis study ,out of 61 endometrial adenocarcinoma cases 33 were positive 
for ER (54%) 
in our current study out of 10 endometrial adenocarcinoma cases 6 cases showed 
positivity (60% )  
 
CHART NO: 6 INCIDENCE OF UTERINE SARCOMAS
NO-7B: COMPARISI
ADENOCARCINOMA
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A.Alkushi et al28
McCluggage et al 
Current study 
 
Mccluggage et al evaluated 30 endometrial adenocarcinoma and 26 endocervical 
adenocarcinomas, in their study 
staebler et al studied 24 endometrial and 24 endocervical adenocarcinomas found that 
only 1 of 24 (4.2%) endocervical 
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TABLE 
 
A.Alkushi et al evaluated 84 endocervical adenocarcinoma , of which 9 cases were 
positive for ER. 
Fujiwara et al study show
positive for ER. 
in our study 3 out of 10 cases showed positivity for ER in Endocervical 
adenocarcinoma biopsies
CHART NO: 7A &B: COMPARISION OF ER EXPRESSION IN WELL 
DIFFRENTIATED ENDOMETRIAL GRADE I ADENOCARCINOMA 
ENDOCERVICAL ADENOCARCINOMA
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CHART NO: 8A &B: COMPARISION OF P16 EXPRESSION IN WELL 
 
 
 
TABLE NO-8A: COMPARISION OF P16 EXPRESSION IN  WELL 
DIFFRENTIATED ENDOMETRIAL ( GRADE I) ADENOCARCINOMA : 
STUDIES       P16 EXPRESSION 
Ansari-Lari et al 31                 35% 
Chih-ping Han et al17                 33% 
McCluggage et al 32                 41% 
Current study                 40% 
 
Ansari et al ,in his study 35 % of cases out of 24 endometrial adenocarcinomas 
showed patchy and weaker positivity. 
Ching-Ping Han et al  study showed 7 out of 21 endometrial adenocarcinoma cases 
stained positive for  P16. 
McCluggage, jenkin et al, in his study on 29 endometrial adenocarcinoma 40% cases  
expressed  weak and patchy p16 
in our study 4 out of 10 cases showed P16 positivity that gives a percentage of 40%  
 
 
 
TABLE NO-8B: 
ENDOCERVICAL ADENOCARCINOMA
STUDIES 
Ansari-Lari et al 31 
Chih-ping Han et al 17 
McCluggage et al 32 
Current study 
CHART NO: 8A &B: COMPARISION OF P16
DIFFRENTIATED ENDOMETRIAL GRADE I ADENOCARCINOMA 
ENDOCERVICAL ADENOCARCINOMA
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Ansari et al, in his study 18 out of 19 endocervical adenocarcinoma cases showed 
strong and diffuse positivity for P16 
Ching-Ping Han et al  study showed 11 out of 14 (79%)  endocervical 
adenocarcinoma cases stained positive for  P16.
McCluggage, jenkin et al, in his study on 23(96 %) endocervical adenocarcinoma  
cases  22 cases expressed diffuse positivity for P16
In our study 9 out of 10 (90%
STUDIES ON PANEL OF MARKERS
 McCluggage et al used 4 marker panel :  ER, CEA, VIMENTIN , 34 
                     Kong cs ,Beck et al
HPV marker ( P16, proExc, HPV ISH . this th
determining the site of origin for usual endometrial and endocervical adenocarcinoma 
however these panel do not perform well with special variants.
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) cases showed  strong and diffuse P16 positivity 
: 
βE12
34 used 3 marker panel:  vimentin , ER or PR , and 
ree panel marker is optimal for 
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                    Steebler et al 35   studied the use of Hormone receptor 
immunohistochemistry and HPV in situ hybridization are useful. 
                   Lai-Fong Kok et al36 study on Reappraisal of  three markers 
(ER/vimentin/CEA), four marker (ER/vimentin/CEA/PR) and five marker 
(ER/vimentin/CEA/PR/P16INK4A) panel in the diagnostic distinction between 
primary endocervical and endometrial adenocarcinoma in a tissue micro array study 
recommends the conventional three marker ER/Vimentin/CEA panel is sufficient, 
appropriate and useful. Ancillary PR and P16 INK 4a add no value to the performance 
of the conventional three marker ER/Vimentin/CEA panel 
 
 
 
INFERENCE : 
No single markers are diagnostic to differentiate between endocervical and 
endometrial adenocarcinomas. 
 p16 is predominantly strong  diffuse positive in endocervical carcinomas31,32 
ER  Marker is predominantly positive in endometrial adenocarcinomas 12,12,16,26,27,28 
Application  of  panel of immunohistochemical markers will be able to distinguish 
endometrial adenocarcinoma from endocervical adenocarcinomas 
Conventional three panel markers  ER/Vimentin/CEA panel is sufficient, appropriate 
and useful. Ancillary PR and P16 INK 4a  add  no value to the performance of the 
conventional three marker ER/Vimentin/CEA panel. 
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CONCLUSION 
1. Uterine corpus malignancies is the third most common malignancies in the female 
genital tract following cervix  and ovary in developing countries like India 
2. It is the first most common female genital tract malignancy in developed countries    
3.. The overall incidence of cases of uterine corpus malignancy in the given period of 
three and half years is 9.6% in Thanjavur medical college and hospital. 
4. The uterine carcinoma carries the percentage of 82% predominantly of 
adenocarcinoma type. 
5. Endometrial adenocarcinoma is the most common malignancy recorded  
6.The other Histological types  received in our study are uterine papillary serous 
carcinoma, clear cell adenocarcinoma , poorly or undifferentiated carcinoma  and  a 
case of squamous cell carcinoma 
6.. In our current study majority of the uterine corpus neoplasms presented in grade I 
disease. with the median age of presentation of 51 years and with a mean age of 52.5 
years. 
7. Endometriod Nos type is most common histological type of endometrial 
adenocarcinoma observed in our study.  
8. Grade I tumors of endometrial adenocarcinoma is  commonly noted  in our study 
than Grade 2 tumors which is mostly common  in other literatures. 
9. In our study 80 % of patients presented in stage I disease  because of earlier 
presentation due to abnormal vaginal bleeding and hence the earlier diagnosis. 
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10. The percentage of uterine sarcomas documented within this period is 9.8% which 
includes the cases of Leiomyosarcoma, Endometrial stromal sarcoma, carcinosarcoma 
Immunohistochemical marker evaluation for ER and P16 on Endometrial 
adenocarcinoma and Endocervical adenocarcinoma.  
1. ER nuclear immuno-histo stain is predominantly positive in endometrial 
adenocarcinomas 12,12,16,26,27,28  in 60% of cases 
2..p16 Immuno-histostaining  showed  predominantly strong  and diffuse positivity in 
endocervical adenocarcinomas31,32 in 90% of cases in our study 
3. Both ER and P16 are positive in 30% of cases 
4. High grade endometrial adenocarcinomas  poorly express ER  
5.No single markers is diagnostic to differentiate between endocervical and 
endometrial adenocarcinomas. 
 4. Panel of immunohistochemical markers will help  to distinguish endometrial 
adenocarcinoma from endocervical adenocarcinomas 
5.Conventional three panel markers  ER/Vimentin/CEA panel is sufficient, 
appropriate and useful. Ancillary PR and P16 INK 4a  add  no value to the 
performance of the conventional three marker ER/Vimentin/CEA panel 
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                                           ANNEXURE I 
WHO Histological Classification of Tumors of the Uterine Corpus 
 
 
Epithelial Tumors and Related Lesions 
 
Endometrial carcinoma 
Endometrioid adenocarcinoma 
Variant with squamous differentiation 
Villoglandular variant 
Secretory variant 
Ciliated cell variant 
Mucinous adenocarcinoma 
Serous adenocarcinoma 
Clear cell adenocarcinoma 
Mixed cell adenocarcinoma 
Squamous cell carcinoma 
Transitional cell carcinoma 
Small cell carcinoma 
Undifferentiated carcinoma 
Others 
Endometrial hyperplasia 
  Nonatypical hyperplasia 
    Simple 
    Complex 
  Atypical hyperplasia 
    Simple 
    Complex 
Endometrial polyp 
Tamoxifen-related lesions 
 
Mesenchymal Tumors 
 
Endometrial stromal and related tumors 
  Endometrial stromal nodule 
  Endometrial stromal sarcoma, low grade 
  Undifferentiated endometrial sarcoma 
Smooth muscle tumors 
  Leiomyosarcoma 
    Epithelioid variant 
    Myxoid variant 
  Smooth muscle tumors of uncertain malignant potential 
  Leiomyoma, not otherwise specified 
    Histological variants 
      Mitotically active variant 
      Cellular variant 
      Hemorrhagic cellular variant 
      Epithelioid variant 
      Myxoid variant 
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      Atypical variant 
      Lipoleiomyoma variant 
    Growth pattern variants 
      Diffuse leiomyomatosis 
        Dissecting leiomyoma 
        Intravenous leiomyomatosis 
        Metastasizing leiomyomatosis 
  Miscellaneous mesenchymal tumors 
    Mixed endometrial stromal and smooth muscle tumors 
    Perivascular epithelioid cell tumor 
    Adenomatoid tumor 
    Other malignant mesenchymal tumors 
    Other benign mesenchymal tumors 
 
Mixed Epithelial and Mesenchymal Tumors 
 
    Carcinosarcoma (malignant mixed Müllerian tumor) 
    Adenosarcoma 
    Carcinofibroma 
    Adenofibroma 
    Adenomyoma 
      Atypical polypoid variant 
 
Gestational Trophoblastic Disease 
 
Trophoblastic neoplasms 
  Choriocarcinoma 
  Placental site trophoblastic tumor 
  Epithelioid trophoblastic tumor 
Molar pregnancies 
  Hydatidiform mole 
    Complete 
    Partial 
    Invasive 
    Metastatic 
Nonneoplastic, nonmolar trophoblastic lesions 
  Placental site nodule and plaque 
  Exaggerated placental site 
 
Miscellaneous Tumors 
 
  Sex cord-like tumors 
  Neuroectodermal tumors 
  Melanotic paraganglioma 
  Tumors of germ cell type 
  Others 
 
Lymphoid and Hematopoietic Tumors 
  Malignant lymphoma 
  Leukemia 
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                                                                      ANNEXURE II 
 
Tumor, Node, Metastasis (TNM) Staging Scheme and FIGO 
of Nontrophoblastic Tumors of the Uterine Corpus 
 
 
PRIMARY TUMOR (T) 
TNM FIGO 
categories Stages 
TX 
 
Primary tumor cannot be assessed 
TO 
 
No evidence of primary tumor 
Tis 0 Carcinoma in situ (preinvasive carcinoma) 
TI I* Tumor confined to corpus uteri 
TIa IA Tumor limited to endometrium 
TIb IB Tumor invades less than one half of myometrium 
TIc 1C Tumor invades one half or more of myometrium 
T2 II Tumor invades cervix but does not extend beyond uterus 
T2a IIA Endocervical glandular involvement only 
T2b IIB Cervical stromal invasion 
T3 and/or 
N1 III 
Local and/or regional spread as specified in T3a, b, N1, and 
FIGO IIIA, B, C below 
T3a IIIA 
Tumor involves serosa and/or adnexa (direct extension or 
metastasis) and/or cancer cells in ascites or peritoneal 
washings 
T3b IIIB Vaginal involvement (direct extension or metastasis) 
T3c IIIC Metastasis to pelvic and/or para-aortic lymph nodes 
T4 IVA Tumor invades bladder mucosa and/or bowel mucosa 
M1 IVB 
Distant metastasis (excluding metastasis to vagina, pelvic 
serosa, or adnexa) 
 
 
 
REGIONAL LYMPH NODES (N) 
NX Regional lymph nodes cannot be assessed 
 
N0 No regional lymph node metastasis 
 
N1 Regional lymph node metastasis 
 
 
 
DISTANT METASTASIS (M) 
MX Distant metastasis cannot be assessed 
 
M0 No distant metastasis 
 
M1 Distant metastasis 
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STAGE GROUPING 
 
Stage 0 Tis N0 M0 
Stage IA T1a N0 M0 
Stage IB T1b N0 M0 
Stage IC T1c N0 M0 
Stage IIA T2a N0 M0 
Stage IIB T2b N0 M0 
Stage IIIA T3a N0 M0 
Stage IIIB T3b N0 M0 
Stage IIIC T1, T2, T3 N1 M0 
Stage IVA T4 Any N M0 
Stage IVB Any T Any N M1 
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ANNEXURE III 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Staging for uterine sarcomas (leiomyosarcomas, endometrial 
stromal sarcomas, Adenosarcomas, and carcinosarcomas) 
 
 
(1) Leiomyosarcoma 
Stage Definition 
 
I 
IA 
IB 
II 
IIA 
IIB 
III 
IIIA 
IIIB 
IV 
IVA 
IVB 
Tumor limited to uterus 
<5 cm 
 >5 cm 
 Tumor extends to the pelvis 
 Adnexal involvement 
Tumor extends to extrauterine pelvic tissue 
 Tumor invades abdominal tissues (not just protruding into the abdomen) 
 One site 
 >One site 
Metastasis to pelvic and/or para-aortic lymph nodes 
Tumor invades bladder and/or rectum 
Distant metastasis 
 
(2) Endometrial stromal sarcomas (ESS) and adenosarcoma
a 
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Simultaneous tumors of the uterine corpus and ovary/pelvis in association with 
ovarian/pelvic endometriosis should be classified as independent primary tumors. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                                                     
 
Stage Definition 
 
I 
IA 
IB 
IC 
II 
IIA 
IIB 
III 
IIIA 
IIIB 
IV 
IVA 
IVB 
Tumor limited to uterus 
 Tumor limited to endometrium/endocervix with no myometrial invasion 
Less than or equal to half myometrial invasion 
 More than half myometrial invasion 
Tumor extends to the pelvis 
 Adnexal involvement 
 Tumor extends to extrauterine pelvic tissue 
 Tumor invades abdominal tissues (not just protruding into the abdomen) 
 One site 
>One site 
 Metastasis to pelvic and/or para-aortic lymph nodes 
 Tumor invades bladder and/or rectum 
 Distant metastasis 
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ANNEXURE IV73 
 Differential microscopic criteria between endometrial hyperplasia and 
adenocarcinoma 
 
                                                          
MICROSCOPIC 
CRITERIA 
ADENOMATOUS 
HYPERPLASIA 
ATYPICAL 
HYPERPLASIA 
ADENOCARCINOMA 
Nuclei 
 Profiles Smooth and oval Irregular Irregular 
 Size Uniform Large, variable Large, variable 
 Nucleoli Small, round Large, irregular 
Large, irregular, 
spiculated 
 Mitoses 
Numerous in stroma 
and glands 
Numerous Variable 
Cytoplasm 
Abundant, 
amphophilic 
Sometimes scant; 
may be very 
abundant, with 
dense eosinophilia 
Scant, pale, amphophilic 
Glands 
 Lining 
epithelium 
Tall columnar, 
single layered 
Stratification, loss 
of polarity 
Loss of polarity 
 Profiles 
Dilated, irregular, 
with outpouching 
and infoldings 
Irregular, with 
intraglandular 
tufting but no 
bridging 
Irregular, with cribriform 
pattern and 
intraglandular bridging 
 Size Variable Variable Variable 
Stroma 
Usually abundant, 
cellular 
Scant, with 
crowding 
Scant 
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                                                        ANNEXURE V 
Criteria and diagnostic terms for uterine smooth muscle tumors (freely adapted 
from the work of Richard Kempson and his co-workers) 
 
 
COAGULATIVE 
NECROSIS 
MITOTIC 
COUNT PER 
10 HPF 
ATYPIA DIAGNOSIS 
Present 
Greater than 
10 
Moderate to severe 
(focal or diffuse) 
Leiomyosarcoma 
None to mild Leiomyosarcoma 
Equal to or 
less than 10 
Moderate to severe 
(focal or diffuse) 
Leiomyosarcoma 
None to mild STUMPa 
Absent 
Greater than 
10 
Moderate to 
severe 
Diffuse Leiomyosarcoma 
Focal STUMPb 
None to mild 
Mitotically active 
leiomyoma (up to 15 
mitoses/10 HPF are 
allowed) 
Equal to or 
less than 10 
Moderate to 
severe 
Diffuse STUMPc 
Focal Leiomyomad 
None to mild Leiomyoma 
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a
 
Of the three tumors here placed in the STUMP category, this is the one most likely 
to behave in a malignant fashion. Actually, it is regarded as a probable 
leiomyosarcoma in Kempson's scheme. The alternative possibility of an infarction in 
a leiomyoma due to torsion or other factors should be considered. 
b
 
In Kempson's scheme, this is designated as STUMP if the mitotic activity is higher 
than 15. 
c
 
This is referred to as ‘atypical leiomyoma with low risk of recurrence’ in Kempson's 
scheme. 
d
 
This is 
designated 
as 
‘leiomyoma 
with limited 
experience’ 
in 
Kempson's 
scheme 
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